Amines, anticonvulsants, and epilepsy.
Concentrations of 5-hydroxyindoleacetic acid (5-H.I.A.T.) in cerebrospinal fluid (C.S.F.) were significantly raised in twenty-seven anticonvulsant-treated epileptic patients compared with fifteen untreated epileptics and twenty-two neurological controls. This rise was not seen until therapeutic blood-levels of phenobarbitone and diphenylhydantoin had been achieved, and was most striking in clinically intoxicated patients. Similar trends were seen in C.S.F. homovanillic acid (H.V.A). There was a close correlation between C.S.F. 5-H.I.A.A. and H.V.A., especially in the treated epileptics. These findings have implications for the antiepileptic and toxic effects of anticonvulsant drugs.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D002849:Chromatography, Gas; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D005470:Fluorometry; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid* / Q000378:metabolism; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid* / Q000378:metabolism; D008875:Middle Aged; D010634:Phenobarbital / Q000097:blood / Q000627:therapeutic use; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D010672:Phenytoin / Q000097:blood / Q000627:therapeutic use; D011324:Primidone / Q000097:blood / Q000627:therapeutic use
D000927:Anticonvulsants; D010648:Phenylacetates; D011324:Primidone; D006897:Hydroxyindoleacetic Acid; D010672:Phenytoin; D006719:Homovanillic Acid; D010634:Phenobarbital